Skip to main content

Table 2 HRQoL utility values as per multi-attribute utility analysis

From: Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer

  Goserelin Chemotherapy
Age 42.6 ± 7.3 45.6 ± 6.5
Mean of SG 0.81 ± 0.17 0.78 ± 0.23
Back to article page